John J. Boniface Sells 21,438 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 21,438 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $9.55, for a total value of $204,732.90. Following the completion of the sale, the insider now directly owns 143,524 shares of the company’s stock, valued at approximately $1,370,654.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Sera Prognostics Stock Down 0.4 %

Sera Prognostics stock opened at $9.46 on Thursday. Sera Prognostics, Inc. has a 52 week low of $1.52 and a 52 week high of $10.44. The stock has a 50-day moving average price of $8.40 and a 200 day moving average price of $5.00.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Sanders Morris Harris LLC boosted its position in Sera Prognostics by 22.6% in the 3rd quarter. Sanders Morris Harris LLC now owns 445,105 shares of the company’s stock worth $828,000 after purchasing an additional 81,933 shares in the last quarter. Resource Consulting Group Inc. acquired a new stake in shares of Sera Prognostics during the 4th quarter worth approximately $265,000. Squarepoint Ops LLC acquired a new stake in shares of Sera Prognostics during the 1st quarter worth approximately $65,000. Bank of New York Mellon Corp acquired a new stake in shares of Sera Prognostics during the 1st quarter worth approximately $50,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Sera Prognostics in the 1st quarter valued at $46,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.